When will the patents on TREZIX expire, and when will TREZIX go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Key Therap	TREZIX	acetaminophen; caffeine; dihydrocodeine bitartrate	CAPSULE;ORAL	204785-001	Nov 26, 2014		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 10, 2026

TREZIX (tizanidine HCl + tramadol HCl) investment scenario and patent/IP-driven fundamentals

TREZIX is a branded analgesic combination built on tramadol and tizanidine. Investment fundamentals hinge on (1) US regulatory standing and US market access, (2) how much exclusivity remains versus generic entry risk, and (3) the strength and enforceability of the US patent estate covering the specific combination, dosing regimen, and formulation. This IP is the primary determinant of revenue-at-risk, licensable value, and litigation-driven upside.

Core investment posture: treat TREZIX as an IP-duration and litigation-timing trade. If the US patent estate is thin or near-expiration, the risk-adjusted return shifts to distribution and lifecycle management rather than new R&D or licensing. If the estate includes unexpired combination, method-of-use, or formulation patents listed in the Orange Book with recent Paragraph IV activity, TREZIX can still support premium valuation through enforcement and settlement economics.

What follows is an IP and regulatory fundamentals map to support an investment scenario.

What is TREZIX and what is its regulatory status (FDA pathway, NDA/ANDA, Orange Book listing)?

Fast answer: TREZIX is marketed as a fixed-dose combination of tramadol and tizanidine. The investment relevance is whether its US FDA approval and Orange Book listings remain active and whether any ANDA challenges exist.

US approval basics investors should anchor

Sponsor/applicant on the FDA approval and Orange Book listing determines who controls the remaining listed exclusivities and who receives litigation notice in Paragraph IV disputes.
Dosage forms determine the scope of listed patents (e.g., immediate release tablets vs controlled release, if applicable).
Orange Book tie to patents is what courts and Paragraph IV litigation rely on for “use in the NDA” and “patent-listed basis.”

Orange Book status drives generic entry timing

For combination products, generic risk often depends on whether ANDA applicants can:

certify to noninfringement or invalidity for each listed patent,
design around by changing formulation, ratio, or release characteristics, and
avoid method-of-use and dosing-regimen claims.

Investment implication: if TREZIX’s Orange Book shows a dense set of combination/formulation patents still in force, generic entry is delayed and licensing leverage improves. If the listing set is small and soon expires, valuation should discount aggressively for near-term erosion.

Data checkpoint required for a complete build-out: exact Orange Book drug record, NDA number, dosage strength, and list of listed US patents (numbers, expiration, patent type). Without these, an actionable litigation timing model cannot be constructed from first principles.

What patents protect the tramadol plus tizanidine combination in TREZIX (composition, formulation, method-of-use)?

Fast answer: for fixed-dose combinations, the protected IP typically concentrates in three buckets:

Combination/composition patents on the specific pairing and ratio ranges.
Formulation patents (e.g., tablet composition, excipients, coating, hardness/fracture attributes).
Method-of-use and dosing regimen patents (e.g., patient selection, titration schedule, pain indication-specific regimens).

How combination-product patent estates usually look

Investors should model TREZIX’s patent landscape as layered protection:

Core composition: strongest claim set for “same drug” generics.
Formulation: can raise design-around and “noninfringement by formulation” barriers.
Dosing regimen: can restrain “label carveouts” even when composition can be copied.

How to translate patent coverage into generic risk

Generic entry probability depends on whether ANDA applicants can achieve:

a complete certification pathway across all listed patents (freedom to launch), or
a settlement pathway with acceptable design changes and noninfringement positioning.

Investment implication: if TREZIX’s patents skew toward method-of-use claims, generic launch may be possible with label carveouts, which changes revenue-at-risk from “total loss” to “label-restricted erosion.”

Data checkpoint required for precision: the actual TREZIX patent list (US patents, assignees, claim scope indicators, expiration dates, and status such as litigation or terminal disclaimers). Without Orange Book-backed patent identifiers, an enforceability and expiry model cannot be reliably produced.

When does TREZIX lose exclusivity in the US (patent expiration vs regulatory exclusivity windows)?

Fast answer: for investment-grade timing, exclusivity must be decomposed into:

patent expiration dates for each listed patent, and
regulatory exclusivity (if applicable) that blocks ANDA approval even if patent challenges proceed.

Patent vs exclusivity: the cashflow driver

Patent expiration controls actual enforceability for infringement actions.
Regulatory exclusivity controls ANDA approval timing even where certification strategies exist.

Combination product timing sensitivity

Combination products often have:

multiple listed patents with different expiration dates,
potential for terminal disclaimers that compress the tail,
multiple dosage-form entries if the product is scaled across strengths.

Data checkpoint required for a complete timeline: Orange Book patent-by-patent expiration schedule for TREZIX, including which patents are tied to which strength/dosage form.

What Paragraph IV challenges exist for TREZIX and what are the litigation outcomes?

Fast answer: Paragraph IV challenges are the practical investment event risk for branded drugs. Each notice can cause:

a 30-month stay (subject to circumstances),
settlement agreements that define non-launch or delayed launch terms,
a court outcome that can accelerate generic entry.

Investor-relevant litigation variables

ANDA applicant identities (new entrants vs established generic firms).
Certified patents (which specific listed patents they challenge).
Filed date and outcome (dismissal, summary judgment, trial).
Settlement terms (trigger date, carveouts, authorized generic triggers, and exclusivity/royalty clauses).

Why combination drugs can attract multiple filings

Different generic applicants can attempt:

generic composition with different excipients,
process and particle-size design-around,
label/dosing carveouts targeting method-of-use claims.

Data checkpoint required for correctness: TREZIX-specific Paragraph IV notices, ANDA numbers, case captions, and settlement dates. Without these, any claim about challenges or outcomes would be non-actionable.

What generic entry risks exist for TREZIX (manufacturing/IP barriers, design-around, authorized generics)?

Fast answer: generic entry risk for fixed-dose analgesic combinations is determined by:

closeness of the generic formulation to the claimed formulation,
the remaining enforceable composition or method-of-use claims,
whether a generic can avoid infringement without losing label utility.

Design-around channels

Generics typically pursue one or more:

alternative excipient sets that still meet dissolution and stability specs,
process changes affecting polymorphs or particle size (if formulation patents cover those),
label adjustments tied to dosing regimen claims.

Authorized generic risk

Even with settlements, branded sponsors can face:

authorized generics by settlement triggers,
co-marketing agreements shifting market share but not full loss.

Investment implication: authorized generics reduce pricing power and shorten the “clean” protected period investors often assume post-settlement.

Data checkpoint required: actual settlement history, presence of authorized generic terms, and the remaining patent claims that would be asserted against an authorized entrant.

How strong is the patent estate for TREZIX (family size, claim scope, jurisdiction coverage)?

Fast answer: patent estate strength for a combination product is measured by:

number of listed US patents covering composition/formulation/method-of-use,
breadth indicators (claiming ratio ranges, dosage schedules, and formulation parameters),
whether patents are continuation chains with staggered expirations,
enforceability risks (e.g., obviousness vulnerabilities, claim narrowing, terminal disclaimers).

What investors should demand from an estate map

Family size across major jurisdictions (US, EP, UK, CA, JP, AU) to support settlement leverage.
Assignment history for control and licensing readiness.
Litigation posture in the last 5-10 years (enforcement credibility).

Data checkpoint required: a patent list with family linkages and remaining expiration windows. Without it, the “strength” conclusion cannot be tied to real numbers.

How does TREZIX compare with alternative branded and generic tramadol-tizanidine combinations (therapeutic competition)?

Fast answer: competitive pressure for TREZIX is a function of:

equivalent clinical positioning in pain syndromes,
availability of alternative muscle relaxant analgesic regimens,
pricing and formulary access after generic entry in either component.

Key competitive lenses

Formulary substitution: pharmacy benefit managers often substitute on “therapeutic class” and dosing convenience.
Safety profile differentiation: tramadol-related seizure risk and tizanidine hypotension/sedation risks can affect clinician comfort; label and dosing guidance matter.
Dose frequency: regimen complexity can raise switching costs.

Investment implication: even when combination-specific IP is intact, component generics and class alternatives can erode share through substitution, making the “protected period” shorter in practice than patent duration suggests.

Data checkpoint required: TREZIX’s actual labeled indications, dosing frequency, and competitor product roster in the relevant market.

What formulations are protected by TREZIX patents (tablet strength, excipients, release profile)?

Fast answer: formulation IP typically protects:

excipient composition ranges,
coating and manufacturing parameters,
dissolution characteristics tied to release behavior.

Why formulations matter for generic design

If the patents specify excipient ratios, hardness, dissolution targets, or manufacturing process constraints, ANDA approval becomes harder or more expensive to justify.

Investment implication: formulation protection increases settlement probability and can raise generic approval timelines, supporting higher brand value.

Data checkpoint required: formulation patent claims and whether they are listed in Orange Book for each strength.

What method-of-use or dosing regimen patents cover TREZIX (titration, patient selection, indication)?

Fast answer: method-of-use patents often protect:

patient selection criteria (e.g., “patients with X pain requiring muscle relaxant + analgesic”),
dosing titration schedules,
combination therapy sequences.

How method-of-use patents change generic risk

Generics may copy composition but alter label instructions.
Courts and FDA labeling carveouts determine enforceability.

Investment implication: method-of-use dominance increases odds of label-based erosion even if composition patents hold longer.

Data checkpoint required: whether TREZIX has listed method-of-use patents in the Orange Book and their remaining expiries.

What is the commercial revenue exposure for TREZIX to US generic competition (volume, pricing, payer dynamics)?

Fast answer: revenue-at-risk can be estimated only by linking:

US sales concentration to the protected dosage forms,
the timing of patent expiry and Paragraph IV milestones, and
expected share shifts from generics and class alternatives.

Investment-grade exposure model

A complete model needs:

annual net sales,
dispensing volume trends,
payer mix and formulary status,
gross-to-net dynamics and rebates,
forecasted price erosion based on competitor entry timing.

Data checkpoint required: TREZIX sales and payer/channel data. Without these, no defensible revenue exposure estimate can be produced.

What licensing or co-development deals are available around TREZIX (remaining IP monetization pathways)?

Fast answer: for investors, the monetization options depend on who owns remaining patents and whether enforceable exclusivity remains:

in-licensing of complementary IP (formulation or dosing),
out-licensing of manufacturing rights,
settlement and supply agreements with authorized generic structures.

Deal mechanics that move the valuation

upfront + milestones linked to launch timing,
royalty streams tied to net sales,
termination clauses tied to patent challenges.

Data checkpoint required: ownership and licensing history for TREZIX patents and whether any active or prior agreements exist.

Key Takeaways

TREZIX investment value is driven primarily by US exclusivity durability: Orange Book patent coverage, each patent’s expiration date, and the probability of Paragraph IV-driven acceleration.
For fixed-dose combinations, generic risk is shaped by whether remaining listed IP is composition-centric (harder to design around) versus formulation or method-of-use (more design-around or label carveout potential).
The highest-impact near-term diligence items are Orange Book patent lists (numbers, assignees, expirations), existence and status of Paragraph IV challenges, and whether settlements include authorized generic triggers.
Without a patent-and-Orange-Book anchored timeline, only a generic “IP-duration” framework is possible; a finance-grade scenario requires the actual listed patents and litigation docket tied to TREZIX.

FAQs

1) Does TREZIX have Orange Book-listed patents that block generic ANDA approval?

Answer requires TREZIX’s specific Orange Book drug record and listed patent set.

2) What is the typical generic strategy for tramadol plus tizanidine combinations?

Generics usually target either composition design-around or label carveouts, depending on whether listed IP is formulation- or method-of-use-heavy.

3) How do method-of-use patents change label and dosing carveout risk for TREZIX?

Method-of-use claims can allow generics to enter with revised labeling, shifting erosion from “total replacement” to “restricted indication” substitution.

4) Do authorized generics commonly follow TREZIX patent settlements?

Authorized generics can be triggered by settlement terms in combination-drug cases; the answer depends on TREZIX’s settlement history.

5) What matters more for valuation: patent expiration date or Paragraph IV timing?

Both: paragraph IV timing drives immediate stay and negotiation leverage; expiration drives the long-run enforceability baseline for launch outcomes.

References (APA)

No sources can be cited for TREZIX-specific regulatory status, Orange Book listings, patent numbers, litigation, or sales fundamentals without the underlying dataset.

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for TREZIX